Patents Assigned to Hadasit Medical Research Services & Development Limited
  • Patent number: 10485792
    Abstract: The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a sustained release drug delivery system comprising a drug for the treatment of this cancer or for the prevention of said lesions, and at least one polymer, such that said system is attached to a surface in the oral cavity and remains attached thereto for at least 1 hour, accompanied by release of the drug and maintaining an effective therapeutic concentration thereof in the cavity, for at least 1 hour. Further are disclosed a sustained release drug delivery system and a liquid precursor varnish composition to this system.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: November 26, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Michael Friedman, Rakefet Czernimski, Silvio Gutkind, Doron Steinberg, Irith Gati, Zakhar Nudelman
  • Patent number: 10464998
    Abstract: This invention relates to methods and compositions for treating fibrosis, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations. In particular, the invention relates to methods and compositions for the treatment of liver fibrosis and/or lung fibrosis. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: November 5, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED
    Inventors: Yaron Ilan, Meir Mizrahi
  • Publication number: 20190264172
    Abstract: Provided is a method of inducing transdifferentiation of mesenchymal stem cells (MSC), the method including (a) culturing MSC in a first culture medium including a growth factor selected for allowing formation of neuralized MSC (NMSC); (b) allowing the NMSC to proliferate for a sufficient time during which said culture medium is renewed at least once; and (c) culturing the NMSC of (b) in a second culture media including cerebrospinal fluid (CSF) for a time sufficient for the NMSC to differentiate into a population of cells including terminally differentiated neurons, astrocytes and oligodendrocytes. Also provided by the present invention is the use of MSC or NMSC for providing a composition including said population and to kits including MSC or NMSC and instructions for use of same.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Applicant: Hadasit Medical Research Services & Development Limited
    Inventors: Dimitrios KARUSSIS, Ibrahim KASSIS
  • Publication number: 20190254992
    Abstract: Provided are therapeutic combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, as well as compositions, kits and methods using the same in treating disorders associated with protein misfolding and for immunomodulation.
    Type: Application
    Filed: June 29, 2017
    Publication date: August 22, 2019
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, SHAARE ZEDEK SCIENTIFIC LTD.
    Inventors: David ARKADIR, Yaron ILAN, Ari ZIMRAN
  • Patent number: 10336985
    Abstract: Provided is a method of inducing transdifferentiation of mesenchymal stem cells (MSC), the method including (a) culturing MSC in a first culture medium including a growth factor selected for allowing formation of neuralized MSC (NMSC); (b) allowing the NMSC to proliferate for a sufficient time during which said culture medium is renewed at least once; and (c) culturing the NMSC of (b) in a second culture media including cerebrospinal fluid (CSF) for a time sufficient for the NMSC to differentiate into a population of cells including terminally differentiated neurons, astrocytes and oligodendrocytes. Also provided by the present invention is the use of MSC or NMSC for providing a composition including said population and to kits including MSC or NMSC and instructions for use of same.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: July 2, 2019
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Dimitrios Karussis, Ibrahim Kassis
  • Patent number: 10314873
    Abstract: A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus Hoodia, wherein the disease is selected from the group consisting of immune-mediated disorders, immune-associated disorders, inflammatory diseases, coronary disease, insulin resistance and liver-related diseases. In a preferred embodiment, the Hoodia is Hoodia parviflora. Also disclosed is a pharmaceutical composition for treating the above diseases comprising an effective dosage of an extract of a plant of the genus Hoodia.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 11, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, DESERT LABS AGRICULTURE COOPERATIVE ASSOCIATION LTD.
    Inventors: Refael Aharon, Yaron Ilan
  • Publication number: 20190134096
    Abstract: Provided are methods and compositions which are applicable for modulating, preventing or treating non-clinical and clinical conditions that are associated with composition of mammalian microbiome. The methods and compositions are based on preparations of hyperimmune colostrum enriched with antibodies for lipopolysaccharides (anti-LPS), which directly or indirectly impact on the composition of mammalian microbiome and are applicable to alleviation and treatment of various forms of renal failure, hypertension, heart disease, atherosclerosis and sepsis, and various psychiatric and neurobehavioral conditions.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 9, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventor: Yaron ILAN
  • Patent number: 10188706
    Abstract: The invention relates to an anti fibrinolytic composition comprising at least one tPA mutant that carries at least one point mutation substituting Ser481 to Ala on tPA, said mutant inhibits the fibrinolytic activity of at least one of tPA and uPA and therefore may be used for treating disorders associated with fibrinolytic processes, specifically, coagulopathies, thrombocytopenia and bleeding. The invention further provides methods and uses of the mutants of the invention.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 29, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Abd Higazi, Nuha Hijazi
  • Patent number: 10174285
    Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 8, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Sharona Cohen Evenram, Benjamin Reubinoff
  • Patent number: 9862925
    Abstract: The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: January 9, 2018
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Michal Aharonowiz, Ofira Einstein, Benjamin Reubinoff, Tamir Ben-Hur
  • Patent number: 9555238
    Abstract: Provided is a device for iontophoretic delivery of a drug to or into a tissue, including an arrangement that prevents operation of the device at a current density that is higher than a predetermined value, the arrangement including first means responsive to a first data item, indicative of the surface area through which the current is to pass, as to set the maximal current allowed at the surface area indicated by the data item. Also provided is a method for iontophorectivally administering drug to or into a tissue, including determining a maximal allowed level of current density and preventing application of current density above the maximal allowed level.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: January 31, 2017
    Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Abraham J. Domb, Joseph Frucht-Pery, Mervyn Shapiro
  • Publication number: 20160251619
    Abstract: Provided is a method of inducing transdifferentiation of mesenchymal stem cells (MSC), the method including (a) culturing MSC in a first culture medium including a growth factor selected for allowing formation of neuralized MSC (NMSC); (b) allowing the NMSC to proliferate for a sufficient time during which said culture medium is renewed at least once; and (c) culturing the NMSC of (b) in a second culture media including cerebrospinal fluid (CSF) for a time sufficient for the NMSC to differentiate into a population of cells including terminally differentiated neurons, astrocytes and oligodendrocytes. Also provided by the present invention is the use of MSC or NMSC for providing a composition including said population and to kits including MSC or NMSC and instructions for use of same.
    Type: Application
    Filed: October 7, 2014
    Publication date: September 1, 2016
    Applicant: Hadasit Medical Research Services & Development Limited
    Inventors: Dimitrios KARUSSIS, Ibrahim KASSIS
  • Publication number: 20160251414
    Abstract: This invention relates to methods and compositions for treating fibrosis, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations. In particular, the invention relates to methods and compositions for the treatment of liver fibrosis and/or lung fibrosis. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.
    Type: Application
    Filed: October 29, 2014
    Publication date: September 1, 2016
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED
    Inventors: Yaron Ilan, Meir Mizrahi
  • Patent number: 9340488
    Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: May 17, 2016
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavy
  • Publication number: 20160097032
    Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.
    Type: Application
    Filed: December 14, 2015
    Publication date: April 7, 2016
    Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Sharona COHEN EVENRAM, Benjamin REUBINOFF
  • Patent number: 9243225
    Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: January 26, 2016
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Sharona Cohen Evenram, Benjamin Reubinoff
  • Patent number: 9205156
    Abstract: Provided is radiolabeled ammonium salts and uses thereof as myocardial perfusion agents in molecular imaging.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: December 8, 2015
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Eyal Mishani, Ohad Ilovich, Hana Billauer, Sharon Dotan, Haim Danenberg, Moshe Bocher, Galith Abourbeh, Nanette Freedman
  • Patent number: 9005965
    Abstract: Provided are systems and methods for providing human cell cultures. Further provided are cultures of feeder cells for use in stem cell technology, as well as cultures, culture systems and methods for maintenance and propagating of stem cells in an undifferentiated state as well as for the development of somatic cells cultures from stem cells, the somatic cell cultures being free of extraembryonic cells.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: April 14, 2015
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Etti Ben Shushan, Shelly Tannenbaum, Pavel Itsykson, Eyal Banin, Benjamin Reubinoff
  • Patent number: 8962891
    Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
    Type: Grant
    Filed: November 9, 2008
    Date of Patent: February 24, 2015
    Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
    Inventors: Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavi
  • Publication number: 20150037404
    Abstract: A method for lubricating a joint of a mammal by administering into a cavity of the joint a composition of liposomes that are multilamellar vesicles (MLV) dispersed in a fluid medium, the liposomes having a mean diameter of between about 0.8 ?m to about 10 ?m and including membranes of at least one glycerophospholipid (GPL) having two C12-C16 hydrocarbon chains which are the same or different. These membranes have a phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, the phase transition temperature being at a temperature of about 20° C. to about 39° C. and being lower than the temperature of the joint.
    Type: Application
    Filed: October 22, 2014
    Publication date: February 5, 2015
    Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Yechezkel BARENHOLZ, Dorit NITZAN, Izhak ETSION, Avi SCHROEDER, Grigory HALPERIN, Sarit SIVAN